Efficacy and safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly compared to tirzepatide 15 mg s.c. once-weekly in participants with obesity

This Study is
No Longer Enrolling

Description

Subjects will be randomly assigned to study medication and receive dietary counseling and be followed over 78 weeks.

Details
Age

Adult

Eligibility

-male or female -age 18 or older -BMI > or = to 30 -Not have type 1 or type 2 diabetes

Type of Study

Treatment

Locations

Anschutz Health and Wellness
Outpatient CTRC

Study ID

Protocol Number: 23-1695

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers